Clinical trial Recruiting at 1 site Observational Ages Any age to 85

Glycosylated ferritin testing for adult Still's disease and macrophage activation syndrome

Official title: Glycosylated Ferritin in Differential Diagnosis of Still's Disease, Sepsis and Other Macrophagic Activation Syndromes.

Run by Brugmann University Hospital · NCT02143986 · Data updated 2026-11-12

This study will test whether measuring the glycosylated portion of ferritin helps diagnose adult-onset Still's disease and macrophage activation syndrome in adults with high ferritin or suspected sepsis.

More Sepsis trials

Quick facts

Study typeObservational
AgesAny age to 85 Years
SexAll
Enrollment60 (estimated)
SponsorBrugmann University Hospital
Academic / other
Locations1 site (Brussels)
StatusRecruiting
StartedMay 2014
Main results expectedDecember 2030
Study endsDecember 2030
Registry record updatedOctober 6, 2025
Trial IDNCT02143986 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with suspected macrophage activation syndrome/HLH, adult-onset Still's disease, unexplained hyperferritinemia, or clinical suspicion of severe sepsis are ideal candidates.

Probably not a fit

Patients with normal ferritin levels or those whose ferritin glycosylation is altered by unrelated conditions (for example severe liver disease or certain malignancies) may not benefit from this test.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study collecting serum from adults with suspected HLH/macrophage activation syndrome or adult-onset Still's disease and from control groups with sepsis, autoimmune inflammation, hepatic necrosis, or hematologic malignancy. The study measures the percentage of glycosylated ferritin and characterizes ferritin glycoforms, including mass spectrometry analysis. Investigators will compare glycosylated ferritin levels and glycoform patterns between diagnostic groups to determine diagnostic performance. Results will be correlated with clinical and laboratory diagnostic criteria recorded by treating physicians.

Why it matters

Potential benefit: If successful, the test could help doctors more accurately distinguish HLH or adult Still's disease from other causes of very high ferritin, enabling faster, more targeted care.

How similar studies have gone: Prior reports have found glycosylated ferritin below 20% in adult Still's disease and HLH and the marker appears in some diagnostic criteria, but it has limitations and is not yet fully validated across diverse control conditions.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Suspicion of sepsis, macrophagic activation syndrome, Still's disease or hyperferritinemia (malignant disease, hepatic cytolysis)

Exclusion Criteria:

* Normal ferritin level

Where it's running

  • Brugmann University Hospital
    Brussels, Belgium
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.